Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

March 22, 2018

Study Completion Date

June 30, 2018

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

AQUABEAM System followed by catheter without hemostatic agent

The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.

DEVICE

AQUABEAM System followed by catheter with hemostatic agent

The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.

Trial Locations (1)

387001

Muljibhai Patel Urological Hospital, Nadiād

Sponsors
All Listed Sponsors
lead

PROCEPT BioRobotics

INDUSTRY

NCT04308070 - Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III | Biotech Hunter | Biotech Hunter